TY - JOUR
KW - Adult
KW - Analgesics, Opioid/blood/urine
KW - Buprenorphine/administration & dosage/adverse effects
KW - Dose-Response Relationship, Drug
KW - Double-Blind Method
KW - Drug Administration Schedule
KW - Female
KW - Humans
KW - Injections
KW - Male
KW - Middle Aged
KW - Narcotic Antagonists/administration & dosage/adverse effects
KW - Opioid-Related Disorders/drug therapy
KW - Patient Compliance
KW - Patient Satisfaction
KW - United States
AU - B. R. Haight
AU - S. M. Learned
AU - C. M. Laffont
AU - P. J. Fudala
AU - Y. Zhao
AU - A. S. Garofalo
AU - M. K. Greenwald
AU - V. R. Nadipelli
AU - W. Ling
AU - C. Heidbreder
AU - RB-US-13-0001 Study Investigators
A1 - 
BT - Lancet (London, England)
C5 - Opioids & Substance Use
CP - 10173
CY - England
IS - 10173
JF - Lancet (London, England)
PB - Elsevier Ltd
PP - England
PY - 2019
SN - 1474-547X; 0140-6736
SP - 778
EP - 790
EP - 
T1 - Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
T2 - Lancet (London, England)
TI - Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
U1 - Opioids & Substance Use
U2 - 30792007
VL - 393
VO - 1474-547X; 0140-6736
Y1 - 2019
ER -